Paper Details

  1. Home
  2. Paper Details

ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.

Author: ChangChawnshang, LiLei, NiuYuanjie, TianJing, WenSimeng, YehShuyuan

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the role of prostate cancer stem/progenitor cells in androgen deprivation therapy (ADT) resistance. The study found that ADT with Casodex or Enzalutamide increased PCa S/P population, while ASC-J9(®) suppressed S/P cell invasion by altering EZH2/STAT3 and AKT/EZH2/STAT3 signals.
Paper Details　
Original Abstract of the Article :
Early studies suggested that prostate cancer (PCa) stem/progenitor (S/P) cells might play key roles to promote the tumor initiation and metastasis. Yet their linkage to the failure of androgen deprivation therapy (ADT), however, remains unclear. Here we demonstrated that the ADT with anti-androgens ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.canlet.2016.01.057

データ提供：米国国立医学図書館（NLM）

ASC-J9: A New Hope for Targeting Prostate Cancer Stem/Progenitor Cells

The field of [oncology] is constantly seeking innovative ways to combat [prostate cancer]. This study investigates the potential of [ASC-J9] in targeting [prostate cancer stem/progenitor (S/P) cells], which are thought to play a crucial role in tumor initiation and metastasis. The authors compare the effects of ASC-J9 to those of other androgen deprivation therapies, [Casodex] and [Enzalutamide].

ASC-J9: A Novel Strategy for Suppressing PCa S/P Cell Invasion

The researchers found that ASC-J9, unlike Casodex and Enzalutamide, effectively suppressed PCa S/P cell invasion by modulating the [EZH2-STAT3 signaling pathway]. This discovery suggests that targeting PCa S/P cells with ASC-J9 or inhibitors of this pathway could be a promising strategy for overcoming the limitations of conventional androgen deprivation therapies.

Navigating the Desert of Prostate Cancer

Prostate cancer can be a formidable adversary, like a shifting sand dune that can evade traditional treatments. This study offers a potential solution, exploring a new approach that targets the very root of the disease – the cancer stem/progenitor cells. It’s like finding a hidden spring in the desert – a source of potential healing and recovery.

Dr.Camel's Conclusion

This research provides a ray of hope in the battle against prostate cancer, highlighting the potential of ASC-J9 in targeting cancer stem/progenitor cells. It’s like discovering a new oasis in the desert of prostate cancer research, offering a promising avenue for developing more effective treatments.

Date :
  1. Date Completed 2017-02-06
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

27045473

DOI: Digital Object Identifier

10.1016/j.canlet.2016.01.057

Related Literature

Article Analysis
・Side Effects of bicalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.